Can migraine meds be safe while breastfeeding? a new study investigates
NCT ID NCT06085144
First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time
Summary
This study looks at how much of the migraine drug galcanezumab (Emgality) appears in breastmilk after a mother receives her usual injections. Researchers will measure drug levels in milk samples from 30 women with migraine who are breastfeeding, and also track infant growth, development, and any side effects like colic or infections. The goal is to fill a gap in knowledge about whether this treatment is safe for nursing mothers and their babies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- galcanezumab (Emgality) injections
- What this could lead to
- If successful, this could provide crucial safety data on using galcanezumab while breastfeeding, potentially expanding treatment options for new mothers with migraine.
- What could go wrong
- This is a small observational study, so results may not apply to all women. It does not test effectiveness, and there is a possibility that drug levels in milk could be higher than expected, though the hypothesis suggests they will be low.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MIGRAINE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of California, San Francisco
RECRUITINGSan Francisco, California, 94158, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a numbing nose treatment stop migraine pain in its tracks?
- Could a symptom registry unmask hidden migraine variants?
- A migraine-blocking antibody tested in children as young as 6
- Mind over migraine: brain network may explain why some expect side effects
- The eyes as a window to the brain: can a simple scan monitor MS, Alzheimer's, and Parkinson's?
- Experimental migraine drug JS010 takes first step in human safety trial